NEWTONE PHARMA LIMITED

Company Registration Number:
08556296 (England and Wales)

Unaudited statutory accounts for the year ended 30 June 2025

Period of accounts

Start date: 01 July 2024

End date: 30 June 2025

NEWTONE PHARMA LIMITED

Contents of the Financial Statements

for the Period Ended 30 June 2025

Company Information - 3
Report of the Directors - 4
Profit and Loss Account - 5
Balance sheet - 6
Additional notes - 8
Balance sheet notes - 11

NEWTONE PHARMA LIMITED

Company Information

for the Period Ended 30 June 2025




Director: Chrysovalentine GARRETT
Registered office: Suite 23018
8 Shepherd Market
Mayfair
London
England
W1J 7JY
Company Registration Number: 08556296 (England and Wales)

NEWTONE PHARMA LIMITED

Directors' Report Period Ended 30 June 2025

The directors present their report with the financial statements of the company for the period ended 30 June 2025

Principal Activities

Wholesale of sugar and chocolate and sugar confectionery Wholesale of pharmaceutical goods Non-specialised wholesale trade

Directors

The directors shown below have held office during the whole of the period from 01 July 2024 to 30 June 2025
Chrysovalentine GARRETT

This report was approved by the board of directors on 27 October 2025
And Signed On Behalf Of The Board By:

Name: Chrysovalentine GARRETT
Status: Director

NEWTONE PHARMA LIMITED

Profit and Loss Account

for the Period Ended 30 June 2025


Notes

2025
£

2024
£
Turnover 879,268 1,014,584
Cost of sales ( 837,351 ) ( 970,481 )
Gross Profit or (Loss) 41,917 44,103
Administrative Expenses ( 1,986 ) ( 1,774 )
Operating Profit or (Loss) 39,931 42,329
Profit or (Loss) Before Tax 39,931 42,329
Tax on Profit ( 7,587 ) ( 8,043 )
Profit or (Loss) for Period 32,344 34,286

The notes form part of these financial statements

NEWTONE PHARMA LIMITED

Balance sheet

As at 30 June 2025


Notes

2025
£

2024
£
Fixed assets
Intangible assets: 4 59,246 59,246
Total fixed assets: 59,246 59,246
Current assets
Cash at bank and in hand: 7,167 17,689
Total current assets: 7,167 17,689
Creditors: amounts falling due within one year: 5 ( 7,587 ) ( 8,043 )
Net current assets (liabilities): ( 420 ) 9,646
Total assets less current liabilities: 58,826 68,892
Creditors: amounts falling due after more than one year: 6 ( 225,813 ) ( 275,813 )
Total net assets (liabilities): ( 166,987 ) ( 206,921 )

The notes form part of these financial statements

NEWTONE PHARMA LIMITED

Balance sheet continued

As at 30 June 2025


Notes

2025
£

2024
£
Capital and reserves
Called up share capital: 1,000 1,000
Profit and loss account: ( 167,987 ) ( 207,921 )
Shareholders funds: ( 166,987 ) ( 206,921 )

For the year ending 30 June 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 27 October 2025
And Signed On Behalf Of The Board By:

Name: Chrysovalentine GARRETT
Status: Director

The notes form part of these financial statements

NEWTONE PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Turnover policy

    Turnover represents the invoiced value of goods and services supplied by the company, net of value-added tax and trade discounts.

NEWTONE PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2025

  • 2. Employees


    2025

    2024
    Average number of employees during the period 0 0

NEWTONE PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2025

  • 3. Off balance sheet disclosure

    No

NEWTONE PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2025

4. Intangible assets

Other Total
Cost £ £
At 01 July 2024 59,246 59,246
Additions - -
Disposals - -
Revaluations - -
Transfers - -
At 30 June 2025 59,246 59,246
Amortisation
Amortisation at 01 July 2024 - -
Charge for year - -
On disposals - -
Other adjustments - -
Amortisation at 30 June 2025 - -
Net book value
Net book value at 30 June 2025 59,246 59,246
Net book value at 30 June 2024 59,246 59,246

Investments

NEWTONE PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2025

5.Creditors: amounts falling due within one year note


2025
£

2024
£
Other creditors 7,587 8,043
Total 7,587 8,043

Corporation tax payable

NEWTONE PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2025

6.Creditors: amounts falling due after more than one year


2025
£

2024
£
Other creditors 225,813 275,813
Total 225,813 275,813